Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
CAROSPIR - official formulation and renal monitoring check
Product / population
CAROSPIR - official formulation and renal monitoring check; selected renal passages, not a complete prescribing monograph.
Renal method
eGFR in mL/min/1.73 m2; preserve body-surface-area indexing.
Source revision
Prescribing information revised September 2023.
Retrieved
2026-09-09
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Suspension non-equivalence and an incompletely specified renal starting instruction
The suspension is not therapeutically equivalent to ALDACTONE tablets. Its renal sentence gives a starting amount without a distinct frequency.
What to reconcile: Do not import a tablet alternate-day schedule. Resolve the frequency in the exact product and indication context.
DailyMed / CMP Pharma, Inc. · CAROSPIR - official formulation and renal monitoring check; selected renal passages, not a complete prescribing monograph.
Renal method: eGFR in mL/min/1.73 m2; preserve body-surface-area indexing. Source date: Prescribing information revised September 2023. Retrieved: 2026-09-09
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Section 2.2 advises considering 10 mg (2 mL) for heart-failure initiation at eGFR 30-50 mL/min/1.73 m2. That renal sentence does not give a distinct administration frequency. CAROSPIR is not therapeutically equivalent to ALDACTONE. Check potassium within one week of starting or titrating, then regularly; closer monitoring may be needed with renal impairment or potassium-raising medicines. Monitor volume status and renal function. Do not silently convert the tablet regimen or invent a dialysis dose.
RDM53-official-spironolactone-carospir-40ccdc8349-C1 · Source locator: Sections 2.1-2.2 and 5.1-5.2; strength 25 mg/5 mL; printed PI revision.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.